Latent autoimmune diabetes in adults – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:32:49 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Latent autoimmune diabetes in adults – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Latent Autoimmune Diabetes in Adults (LADA) Patients: Evaluating Diabetes Status 3 Years After Treatment with Glutamate Decarboxylase 2 https://clinicaltrials.eu/trial/study-on-latent-autoimmune-diabetes-in-adults-lada-patients-evaluating-diabetes-status-3-years-after-treatment-with-glutamate-decarboxylase-2/ Wed, 29 Apr 2026 14:29:43 +0000 https://clinicaltrials.eu/trial/study-on-latent-autoimmune-diabetes-in-adults-lada-patients-evaluating-diabetes-status-3-years-after-treatment-with-glutamate-decarboxylase-2/ This clinical trial is focused on studying a type of diabetes known as Latent Autoimmune Diabetes in Adults (LADA). LADA is a form of diabetes that shares characteristics with both Type 1 and Type 2 diabetes. The treatment being investigated in this study is called GAD-alum, which is a suspension for injection containing a substance known as glutamate decarboxylase 2, human, recombinant. This treatment is administered through a method called intralymphatic use, which involves injecting the treatment into the lymph nodes.

The purpose of this study is to examine the long-term effects of GAD-alum on diabetes status and immune system parameters in individuals who have previously participated in a related study. Specifically, the study aims to determine if there are differences in diabetes status between individuals who carry a specific genetic marker, known as HLA-DR3DQ2, and those who do not. This will be assessed three years after the initial treatment with GAD-alum.

Participants in this study will undergo assessments to evaluate their diabetes status, focusing on their body’s ability to produce insulin and maintain metabolic control. These assessments will help researchers understand the potential long-term benefits of GAD-alum treatment for people with LADA. The study is a follow-up to a previous trial, and it will provide valuable insights into the effectiveness of this treatment over an extended period.

]]>